Publications

Add filters (0)

386 results

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.

July 1, 2023

Hepatology

Abstract BACKGROUND AND AIMS Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD. APPROACH AND RESULTS Learning data were […]

Read publication

Biomarkers for osteoarthritis: Current status and future prospects.

June 1, 2023

Best Pract Res Clin Rheumatol

Abstract Osteoarthritis (OA) is the most common form of arthritis globally and a major cause of pain, physical disability, and loss of economic productivity, with currently no causal treatment available. This review article focuses on current research on OA biomarkers and the potential for using biomarkers in future clinical practice and clinical trials of investigational […]

Read publication

Novel fibro-inflammatory biomarkers associated with disease activity in patients with Crohn’s disease.

June 1, 2023

Expert Rev Gastroenterol Hepatol

Abstract INTRODUCTION Crohn’s disease (CD) is a complex disease, and assessing activity is challenging due to pathobiologic process e.g. ECM remodeling, mucosal damage, and intestinal fibrosis, which greatly limits current disease activity assessments through e.g. endoscopy and imaging techniques. AREAS COVERED The review highlights the importance of novel biomarkers reflecting ECM remodeling and immune cell […]

Read publication

Relevance of Biomarkers in Serum vs. Synovial Fluid in Patients with Knee Osteoarthritis.

May 30, 2023

Int J Mol Sci

Abstract The association between structural changes and pain sensation in osteoarthritis (OA) remains unclear. Joint deterioration in OA leads to the release of protein fragments that can either systemically (serum) or locally (synovial fluid; SF) be targeted as biomarkers and describe structural changes and potentially pain. Biomarkers of collagen type I (C1M), type II (C2M), […]

Read publication

Structural changes after ankle joint distraction in haemophilic arthropathy: an explorative study investigating biochemical markers and 3D joint space width.

May 1, 2023

Haemophilia

Abstract INTRODUCTION Ankle joint distraction (AJD) is a promising treatment for patients with severe haemophilic ankle arthropathy (HAA). However, some patients showed no clinical improvement after AJD and these differences may be related to structural differences. AIM Primarily to quantify the structural changes after AJD in patients with HAA by the use of 3D joint […]

Read publication

Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation.

April 13, 2023

Sci Rep

Abstract Detecting patients with early post-transplant fibrosis after liver transplantation (LT) is very important. Non-invasive tests are needed to avoid liver biopsies. We aimed to detect fibrosis in liver transplant recipients (LTR) using extracellular matrix (ECM) remodeling biomarkers. ECM biomarkers for type III (PRO-C3), IV (PRO-C4), VI (PRO-C6) and XVIII (PRO-C18L) collagen formation and type […]

Read publication

Autoreactivity against Denatured Type III Collagen Is Significantly Decreased in Serum from Patients with Cancer Compared to Healthy Controls.

April 11, 2023

Int J Mol Sci

Abstract Autoantibodies have the potential as cancer biomarkers as they may associate with the outcome and immune-related adverse events (irAEs) following immunotherapy. Cancer and other fibroinflammatory diseases, such as rheumatoid arthritis (RA), are associated with excessive collagen turnover leading to collagen triple helix unfolding and denaturation with exposure of immunodominant epitopes. In this study, we […]

Read publication

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned.

April 1, 2023

J Hepatol

Abstract Biomarkers have the potential to accelerate drug development, as early indicators of improved clinical response, to improve patient safety, and for personalised medicine. However, few have been approved through the biomarker qualification pathways of the regulatory agencies. This paper outlines how biomarkers can accelerate drug development, and reviews the lessons learned by the EU […]

Read publication

Differentiating patients with psoriasis from psoriatic arthritis using collagen biomarkers.

March 1, 2023

Clin Exp Rheumatol

Abstract OBJECTIVES Around 30% of patients diagnosed with cutaneous psoriasis (PsC) will go on to develop psoriatic arthritis (PsA) which includes inflammation of the joints. Collagens are core proteins in all tissues, which are involved in the inflammatory process in both PsC and PsA. The aim of this study is to investigate collagen biomarkers and […]

Read publication

Serum biomarkers in prednisolone-treated hand osteoarthritis patients.

March 1, 2023

Rheumatology (Oxford)

Abstract OBJECTIVES To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand OA and whether they can predict response to prednisolone. METHODS Biomarkers reflecting tissue turnover and inflammation [aggrecanase-derived neoepitope of arggecan (ARGS), MMP-derived neoepitope of type I collagen (C1M), MMP-derived neoepitope of type III collagen (C3M), marker of true type V […]

Read publication